Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Albert Rizzo

Pulmonary Disease Newark, DE Medical Doctor

NPI 1245283316 CMS profile 55769

4745 Ogletown Stanton Rd, Suite 220, Newark, DE 19713

Open in the dashboard

General payments

$161,804

217 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Albert Rizzo of Newark, DE is reported in the CMS Open Payments database as having received $161,804 across 217 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,585 2
2024 General $2,674 5
2023 General $9,043 13
2022 General $7,188 18
2021 General $25,066 27
2020 General $39,414 38
2019 General $67,834 114

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Albert Rizzo
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Albert Rizzo were reported at $10,585. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Albert Rizzo Pulmonary Disease median Middle half National median
2019 $67,834 $377 $109–$1,340 $163
2020 $39,414 $230 $56–$907 $114
2021 $25,066 $269 $68–$1,072 $132
2022 $7,188 $390 $100–$1,457 $149
2023 $9,043 $419 $114–$1,659 $160
2024 $2,674 $476 $123–$1,818 $164
2025 $10,585 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $50,407 57 payments
  2. Genzyme Corporation $27,814 19 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $21,408 31 payments
  4. Regeneron Healthcare Solutions, Inc. $16,644 29 payments
  5. Mylan Specialty L.P. $13,293 17 payments
  6. Moderna TX, Inc. $7,621 5 payments
  7. Sunovion Pharmaceuticals Inc. $4,979 12 payments
  8. Pfizer Inc. $4,529 8 payments
  9. Novartis Pharmaceuticals Corporation $4,224 7 payments
  10. Merck Sharp & Dohme Corporation $3,830 5 payments
  11. Other $7,056 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $119,749 64 payments
  2. Consulting Fee $27,552 18 payments
  3. Travel and Lodging $9,220 45 payments
  4. Food and Beverage $5,270 87 payments
  5. Education $13 3 payments
Products named General payments · program years 2019–2025
  1. NUCALA Respiratory $17,424 18 payments
  2. DUPIXENT Inflammation And Immunology $16,644 29 payments
  3. TRELEGY ELLIPTA $14,152 12 payments
  4. DUPIXENT Immunology $11,565 10 payments
  5. Yupelri $10,766 13 payments
  6. Moderna Covid-19 Vaccine $7,621 5 payments
  7. ANORO ELLIPTA $6,137 6 payments
  8. NUCALA Immunology $6,044 9 payments
  9. DUPIXENT Immunology $5,664 7 payments
  10. LONHALA MAGNAIR $4,964 11 payments
  11. Other $16,738 45 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

217 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Delaware

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record